{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:28:55Z","timestamp":1787020135460,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007653","name":"Universit\u00e4tsklinikum Jena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007653","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The German Parkinson\u00b4s disease multimodal complex treatment (PD-MCT) is a structured multidisciplinary inpatient treatment for people with Parkinson\u2019s disease (PwPD). However, data on its long-term effect are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A monocentric, non-blinded, clinical trial with randomized allocation and six-month follow-up was conducted at the Department of Neurology of the Jena University Hospital. At total of 120 patients admitted for PD-MCT were allocated 1:1 to two predefined treatment durations (short: 7\u201313 days; long: 14\u201320 days) according to the German Operation and Procedure Classification System (OPS; code 8-97d). The primary outcome was change in the Movement Disorder Society sponsored revision of the unified Parkinson\u2019s disease rating scale (MDS-UPDRS) part II after six months. Secondary outcomes included change in quality of life assessed by the Parkinson\u2019s Disease Questionnaire 8 (PDQ-8) and the influence of treatment duration. Analyses were performed as-treated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In 93 PwPD, MDS-UPDRS II improved by 3 points (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.435;\n                      <jats:italic>p<\/jats:italic>\n                      &lt;\u20090.001), with 52.7% achieving a clinically relevant improvement. Improvement was associated with higher baseline MDS-UPDRS II (odds ratio [OR] 1.16, 95% confidence interval [CI] 1.07\u20131.27;\n                      <jats:italic>p<\/jats:italic>\n                      &lt;\u20090.001), lower Hoehn and Yahr stage (OR 0.29, 95% CI 0.09\u20130.97;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.045), and fewer nonmotor symptoms (OR 0.88, 95% CI 0.77-1.00;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.042) (\n                      <jats:italic>x<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      (3)\u2009=\u200914.94;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002;\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.22). PDQ-8 improved by 8 points (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.524;\n                      <jats:italic>p<\/jats:italic>\n                      &lt;\u20090.001), with 58.1% showing clinically relevant improvement, which was associated with lower Hoehn and Yahr stage (OR 0.30, 95% CI 0.10\u20130.92;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.035), and more depressive symptoms (OR 1.17, 95% CI 1.04\u20131.33;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012) (\n                      <jats:italic>x<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      (2)\u2009=\u200910.53;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005;\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.15). Treatment duration had no significant influence on MDS-UPDRS II (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.611, Eta\u00b2 = 0.001) or PDQ-8 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.809, Eta\u00b2 = 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PD-MCT is an effective multidisciplinary inpatient treatment with clinically relevant long-term effects up to six months. In clinical practice, the shorter treatment duration may be similarly effective in selected patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      German Clinical Trials Register, DRKS00025225, registered 30 June 2021,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/drks.de\/search\/de\/trial\/DRKS00025225\" ext-link-type=\"uri\">https:\/\/drks.de\/search\/de\/trial\/DRKS00025225<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-026-05039-5","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T23:36:36Z","timestamp":1780529796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term effect of the German Parkinson\u2019s disease multimodal complex treatment: a clinical trial with randomized allocation"],"prefix":"10.1186","volume":"26","author":[{"given":"Konstantin G.","family":"Heimrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Sch\u00f6nenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Mendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah M.","family":"M\u00fchlhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Teschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Brodoehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tino","family":"Prell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"5039_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/bs.irn.2017.02.016","volume":"132","author":"N Titova","year":"2017","unstructured":"Titova N, Qamar MA, Chaudhuri KR. The Nonmotor Features of Parkinson\u2019s Disease. Int Rev Neurobiol. 2017;132:33\u201354. https:\/\/doi.org\/10.1016\/bs.irn.2017.02.016.","journal-title":"Int Rev Neurobiol"},{"key":"5039_CR2","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamaneurol.2015.0703","volume":"72","author":"S-M Fereshtehnejad","year":"2015","unstructured":"Fereshtehnejad S-M, Romenets SR, Anang JBM, Latreille V, Gagnon J-F, Postuma RB. New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression: A Prospective Cohort Comparison With Other Phenotypes. JAMA Neurol. 2015;72:863\u201373. https:\/\/doi.org\/10.1001\/jamaneurol.2015.0703.","journal-title":"JAMA Neurol"},{"key":"5039_CR3","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/brain\/awx118","volume":"140","author":"S-M Fereshtehnejad","year":"2017","unstructured":"Fereshtehnejad S-M, Zeighami Y, Dagher A, Postuma RB. Clinical criteria for subtyping Parkinson\u2019s disease: biomarkers and longitudinal progression. Brain. 2017;140:1959\u201376. https:\/\/doi.org\/10.1093\/brain\/awx118.","journal-title":"Brain"},{"key":"5039_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/mds.23462","volume":"26","author":"P Martinez-Martin","year":"2011","unstructured":"Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR, Group on B of the NV. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson\u2019s disease. Mov Disord. 2011;26:399\u2013406. https:\/\/doi.org\/10.1002\/mds.23462.","journal-title":"Mov Disord"},{"key":"5039_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.parkreldis.2019.07.031","volume":"66","author":"DS Garc\u00eda","year":"2019","unstructured":"Garc\u00eda DS, Fonticoba T, de D, Castro ES, Borru\u00e9 C, Mata M, Vila BS, et al. Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson\u2019s disease patients: Results from the COPPADIS Study Cohort. Parkinsonism Relat Disord. 2019;66:151\u20137. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.07.031.","journal-title":"Parkinsonism Relat Disord"},{"key":"5039_CR6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/bs.irn.2017.05.023","volume":"133","author":"P Barone","year":"2017","unstructured":"Barone P, Erro R, Picillo M. Quality of Life and Nonmotor Symptoms in Parkinson\u2019s Disease. Int Rev Neurobiol. 2017;133:499\u2013516. https:\/\/doi.org\/10.1016\/bs.irn.2017.05.023.","journal-title":"Int Rev Neurobiol"},{"key":"5039_CR7","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020;323:548\u201360. https:\/\/doi.org\/10.1001\/jama.2019.22360.","journal-title":"JAMA"},{"key":"5039_CR8","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C. Parkinson\u2019s disease. Lancet. 2021;397:2284\u2013303. https:\/\/doi.org\/10.1016\/S0140-6736(21)00218-X.","journal-title":"Lancet"},{"key":"5039_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3390\/cells8020151","volume":"8","author":"D Richter","year":"2019","unstructured":"Richter D, Bartig D, Muhlack S, Hartelt E, Scherbaum R, Katsanos AH, et al. Dynamics of Parkinson\u2019s Disease Multimodal Complex Treatment in Germany from 2010\u20132016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers. Cells. 2019;8:151. https:\/\/doi.org\/10.3390\/cells8020151.","journal-title":"Cells"},{"key":"5039_CR10","unstructured":"Statistisches Bundesamt (Destatis). Fallpauschalenbezogene Krankenhausstatistik (DRG-Statistik) Operationen und Prozeduren der vollstation\u00e4ren Patientinnen und Patienten in Krankenh\u00e4usern (4-Steller)\u2009\u2013\u20092022. 2023."},{"key":"5039_CR11","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00702-017-1701-3","volume":"124","author":"T M\u00fcller","year":"2017","unstructured":"M\u00fcller T, \u00d6hm G, Eilert K, M\u00f6hr K, Rotter S, Haas T, et al. Benefit on motor and non-motor behavior in a specialized unit for Parkinson\u2019s disease. J Neural Transm. 2017;124:715\u201320. https:\/\/doi.org\/10.1007\/s00702-017-1701-3.","journal-title":"J Neural Transm"},{"key":"5039_CR12","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s00415-019-09657-7","volume":"267","author":"R Scherbaum","year":"2020","unstructured":"Scherbaum R, Hartelt E, Kinkel M, Gold R, Muhlack S, T\u00f6nges L. Parkinson\u2019s Disease Multimodal Complex Treatment improves motor symptoms, depression and quality of life. J Neurol. 2020;267:954\u201365. https:\/\/doi.org\/10.1007\/s00415-019-09657-7.","journal-title":"J Neurol"},{"key":"5039_CR13","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.3390\/jcm9061874","volume":"9","author":"E Hartelt","year":"2020","unstructured":"Hartelt E, Scherbaum R, Kinkel M, Gold R, Muhlack S, T\u00f6nges L. Parkinson\u2019s Disease Multimodal Complex Treatment (PD-MCT): Analysis of Therapeutic Effects and Predictors for Improvement. J Clin Med. 2020;9:1874. https:\/\/doi.org\/10.3390\/jcm9061874.","journal-title":"J Clin Med"},{"key":"5039_CR14","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.3390\/brainsci11111460","volume":"11","author":"KG Heimrich","year":"2021","unstructured":"Heimrich KG, Prell T. Short- and Long-Term Effect of Parkinson\u2019s Disease Multimodal Complex Treatment. Brain Sci. 2021;11:1460. https:\/\/doi.org\/10.3390\/brainsci11111460.","journal-title":"Brain Sci"},{"key":"5039_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/mdc3.13578","volume":"10","author":"K Ziegler","year":"2022","unstructured":"Ziegler K, Messner M, Paulig M, Starrost K, Reuschenbach B, Fietzek UM, et al. Activities of Daily Living Are Improved by Inpatient Multimodal Complex Treatment for PD\u2014a Real-World Cohort Study. Mov Disord Clin Pract. 2022;10:42\u201354. https:\/\/doi.org\/10.1002\/mdc3.13578.","journal-title":"Mov Disord Clin Pract"},{"key":"5039_CR16","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 2015;30:1591\u2013601. https:\/\/doi.org\/10.1002\/mds.26424.","journal-title":"Mov Disord"},{"key":"5039_CR17","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23:2129\u201370. https:\/\/doi.org\/10.1002\/mds.22340.","journal-title":"Mov Disord"},{"key":"5039_CR18","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/08870449708406741","volume":"12","author":"C Jenkinson","year":"1997","unstructured":"Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The PDQ-8: Development and validation of a short-form parkinson\u2019s disease questionnaire. Psychol Health. 1997;12:805\u201314. https:\/\/doi.org\/10.1080\/08870449708406741.","journal-title":"Psychol Health"},{"key":"5039_CR19","unstructured":"Jenkinson C, Fitzpatrick R, Peto V, Harris R, Saunders P. PDQ-39 user manual (including PDQ-8 and PDQ summary index). The parkinson\u2019s disease questionnaire. 2008."},{"key":"5039_CR20","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/mds.20213","volume":"19","author":"CG Goetz","year":"2004","unstructured":"Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19:1020\u20138. https:\/\/doi.org\/10.1002\/mds.20213.","journal-title":"Mov Disord"},{"key":"5039_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/mdc3.12921","volume":"7","author":"S Schade","year":"2020","unstructured":"Schade S, Mollenhauer B, Trenkwalder C. Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide. Mov Disord Clin Pract. 2020;7:343\u20135. https:\/\/doi.org\/10.1002\/mdc3.12921.","journal-title":"Mov Disord Clin Pract"},{"key":"5039_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.parkreldis.2011.08.013","volume":"18","author":"SR Romenets","year":"2012","unstructured":"Romenets SR, Wolfson C, Galatas C, Pelletier A, Altman R, Wadup L, et al. Validation of the non-motor symptoms questionnaire (NMS-Quest). Parkinsonism Relat Disord. 2012;18:54\u20138. https:\/\/doi.org\/10.1016\/j.parkreldis.2011.08.013.","journal-title":"Parkinsonism Relat Disord"},{"key":"5039_CR23","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695\u20139. https:\/\/doi.org\/10.1111\/j.1532-5415.2005.53221.x.","journal-title":"J Am Geriatr Soc"},{"key":"5039_CR24","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. J Gen Intern Med. 2001;16:606\u201313. https:\/\/doi.org\/10.1046\/j.1525-1497.2001.016009606.x.","journal-title":"J Gen Intern Med"},{"key":"5039_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1532-5415.1986.tb05480.x","volume":"34","author":"ME Tinetti","year":"1986","unstructured":"Tinetti ME. Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc. 1986;34:119\u201326. https:\/\/doi.org\/10.1111\/j.1532-5415.1986.tb05480.x.","journal-title":"J Am Geriatr Soc"},{"key":"5039_CR26","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/mds.26960","volume":"32","author":"K Horv\u00e1th","year":"2017","unstructured":"Horv\u00e1th K, Aschermann Z, Kov\u00e1cs M, Makkos A, Harmat M, Janszky J, et al. Minimal clinically important differences for the experiences of daily living parts of movement disorder society-sponsored unified Parkinson\u2019s disease rating scale. Mov Disord. 2017;32:789\u201393. https:\/\/doi.org\/10.1002\/mds.26960.","journal-title":"Mov Disord"},{"key":"5039_CR27","doi-asserted-by":"publisher","unstructured":"Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd edition. New York: Routledge; 1988. https:\/\/doi.org\/10.4324\/9780203771587.","DOI":"10.4324\/9780203771587"},{"key":"5039_CR28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/mds.22240","volume":"24","author":"N Luo","year":"2009","unstructured":"Luo N, Tan LCS, Zhao Y, Lau P-N, Au W-L, Li SC. Determination of the longitudinal validity and minimally important difference of the 8-item Parkinson\u2019s Disease Questionnaire (PDQ-8). Mov Disord. 2009;24:183\u20137. https:\/\/doi.org\/10.1002\/mds.22240.","journal-title":"Mov Disord"},{"key":"5039_CR29","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s00702-017-1707-x","volume":"124","author":"R Kr\u00fcger","year":"2017","unstructured":"Kr\u00fcger R, Klucken J, Weiss D, T\u00f6nges L, Kolber P, Unterecker S, et al. Classification of advanced stages of Parkinson\u2019s disease: translation into stratified treatments. J Neural Transm (Vienna). 2017;124:1015\u201327. https:\/\/doi.org\/10.1007\/s00702-017-1707-x.","journal-title":"J Neural Transm (Vienna)"},{"key":"5039_CR30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/mds.25664","volume":"29","author":"GW Duncan","year":"2014","unstructured":"Duncan GW, Khoo TK, Yarnall AJ, O\u2019Brien JT, Coleman SY, Brooks DJ, et al. Health-related quality of life in early Parkinson\u2019s disease: the impact of nonmotor symptoms. Mov Disord. 2014;29:195\u2013202. https:\/\/doi.org\/10.1002\/mds.25664.","journal-title":"Mov Disord"},{"key":"5039_CR31","doi-asserted-by":"publisher","first-page":"4616","DOI":"10.3390\/jcm12144616","volume":"12","author":"KG Heimrich","year":"2023","unstructured":"Heimrich KG, Mendorf S, Sch\u00f6nenberg A, Santos-Garc\u00eda D, Mir P, Coppadis Study Group null. Depressive Symptoms and Their Impact on Quality of Life in Parkinson\u2019s Disease: An Exploratory Network Analysis Approach. J Clin Med. 2023;12:4616. https:\/\/doi.org\/10.3390\/jcm12144616.","journal-title":"J Clin Med"},{"key":"5039_CR32","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1037\/neu0000739","volume":"35","author":"SL Stohlman","year":"2021","unstructured":"Stohlman SL, Barrett MJ, Sperling SA. Factor structure of the BDI-II in Parkinson\u2019s disease. Neuropsychology. 2021;35:540\u20136. https:\/\/doi.org\/10.1037\/neu0000739.","journal-title":"Neuropsychology"},{"key":"5039_CR33","doi-asserted-by":"publisher","first-page":"8857385","DOI":"10.1155\/2020\/8857385","volume":"2020","author":"R Tuijt","year":"2020","unstructured":"Tuijt R, Tan A, Armstrong M, Pigott J, Read J, Davies N, et al. Self-Management Components as Experienced by People with Parkinson\u2019s Disease and Their Carers: A Systematic Review and Synthesis of the Qualitative Literature. Parkinsons Dis. 2020;2020:8857385. https:\/\/doi.org\/10.1155\/2020\/8857385.","journal-title":"Parkinsons Dis"},{"key":"5039_CR34","doi-asserted-by":"publisher","unstructured":"Dorsey ER, Sherer T, Okun MS, Bloem BR. The Emerging Evidence of the Parkinson Pandemic. J Parkinsons Dis 8 Suppl 1:S3\u20138. https:\/\/doi.org\/10.3233\/JPD-181474.","DOI":"10.3233\/JPD-181474"},{"key":"5039_CR35","doi-asserted-by":"publisher","first-page":"1136858","DOI":"10.3389\/fneur.2023.1136858","volume":"14","author":"NS Shaibdat","year":"2023","unstructured":"Shaibdat NS, Ahmad N, Azmin S, Ibrahim NM. Causes, factors, and complications associated with hospital admissions among patients with Parkinson\u2019s disease. Front Neurol. 2023;14:1136858. https:\/\/doi.org\/10.3389\/fneur.2023.1136858.","journal-title":"Front Neurol"},{"key":"5039_CR36","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.3233\/JPD-230271","volume":"14","author":"E Steendam-Oldekamp","year":"2024","unstructured":"Steendam-Oldekamp E, van Laar T. The Effectiveness of Inpatient Rehabilitation in Parkinson\u2019s Disease: A Systematic Review of Recent Studies. J Parkinsons Dis. 2024;14:S93\u2013112. https:\/\/doi.org\/10.3233\/JPD-230271.","journal-title":"J Parkinsons Dis"},{"key":"5039_CR37","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jama.2021.2825","volume":"326","author":"VA Smith","year":"2021","unstructured":"Smith VA, Coffman CJ, Hudgens MG. Interpreting the Results of Intention-to-Treat, Per-Protocol, and As-Treated Analyses of Clinical Trials. JAMA. 2021;326:433\u20134. https:\/\/doi.org\/10.1001\/jama.2021.2825.","journal-title":"JAMA"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-05039-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05039-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05039-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T08:23:38Z","timestamp":1780907018000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-05039-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5039"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-05039-5","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of the Jena University Hospital (registration number 2021-2228-BO). Written informed consent was obtained from all participants in this study before inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"372"}}